Health Condition 1: N850- Endometrial hyperplasia Health Condition 2: N921- Excessive and frequent menstruation with irregular cycle Health Condition 3: N945- Secondary dysmenorrhea
Conditions
Interventions
Intervention1: Levenorgestrel releasing intrauterine system: Releases 20 microgram levenorgestrel per day to control heavy menstrual bleeding. It is inserted only once in 5years in the intrauterine ca
Sponsors
ESI MEDICAL COLLEGE, JOKA
Eligibility
Inclusion criteria
Inclusion criteria: All women having heavy menstrual bleeding with or without associated dysmenorrhea or chronic pelvic pain All women with histologically proven endometrial hyperplasia without atypia or any other benign endometrial pathology Fibroid uterus Adenomyosis Medical or surgical high-risk factors making the subjects unsuitable for surgery Age group between 30-50 years
Exclusion criteria
Exclusion criteria: Active genital infection Suspicion of pregnancy, malignancy Uterine fibroids or submucosal fibroid distorting the endometrial cavity Atypical endometrial hyperplasia or malignancy Abnormal cervical cytology and malignancy Haematological disease, abnormal coagulopathy Liver disease, uncontrolled diabetes mellitus H/o arterial or venous thromboembolic disorders Women who are willing to conceive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in the menstrual bleeding Increase of Hb level at 3 monthly interval Decrease in the endometrial thicknessTimepoint: after 4 weeks of administration and then every 3 monthly till 1year | — |
Secondary
| Measure | Time frame |
|---|---|
| Decrease of pain Satisfaction level Discontinuation of therapy and its cause Treatment failure Management after treatment failureTimepoint: after 1 week of administration, then after 4 weeks, every 3 monthly for 1 year | — |
Countries
India
Contacts
Public ContactSUMANA SARKAR
ESIPGIMSR AND ESIC MEDICAL COLLEGE JOKA
Outcome results
None listed